Drug shortage: Dopamine Hydrochloride Injection (DOPAMINE HYDROCHLORIDE AND DEXTROSE, DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE IN DEXTROSE)
FDA lists 11 presentations as Current. Availability: Unavailable (3), Available (8). Reason: Demand increase for the drug; Other. Companies: Baxter Healthcare, Hikma Pharmaceuticals USA, Inc., Hospira, Inc., a Pfizer Company.
- Published by source
- 2017-11-06
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Baxter Healthcare
- Products
- Dopamine Hydrochloride Injection DOPAMINE HYDROCHLORIDE AND DEXTROSE DOPAMINE HYDROCHLORIDE DOPAMINE HYDROCHLORIDE IN DEXTROSE
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: Current — Unavailable
Remedy / actions:
- Additional lots will be available in the November 2026 timeframe. Product will be made available as it is released.
- Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2017-11-06
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #912 | new | 2026-10-22 | e8d9e7cb868f…a354a2 | b6fa01eae13f…e0adf9 |
Chain head: #1094 edf3be25ec2e…478842